Clene Inc.

2.90+0.1300+4.69%Vol 2.29M1Y Perf -75.18%
Jun 24th, 2022 16:00 DELAYED
BID2.63 ASK3.57
Open2.86 Previous Close2.77
Pre-Market- After-Market2.90
 - -  - -%
Target Price
14.50 
Analyst Rating
Strong Buy 1.00
Potential %
400.00 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+     42.02
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
6.10 
Earnings Rating
Market Cap183.44M 
Earnings Date
9th Aug 2022
Alpha-0.05 Standard Deviation0.33
Beta1.61 

Today's Price Range

2.783.15

52W Range

1.9317.82

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
22.36%
1 Month
22.88%
3 Months
-3.97%
6 Months
-33.64%
1 Year
-75.18%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CLNN2.900.13004.69
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.18-0.21-16.67
Q04 2021-0.18-0.19-5.56
Q03 2021-0.22-0.0386.36
Q02 2021-0.10-0.21-110.00
Q01 2021-0.09-0.19-111.11
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date9th Aug 2022
Estimated EPS Next Report-0.20
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume2.29M
Shares Outstanding63.26K
Shares Float34.35M
Trades Count4.26K
Dollar Volume6.67M
Avg. Volume303.82K
Avg. Weekly Volume439.48K
Avg. Monthly Volume295.89K
Avg. Quarterly Volume176.09K

Clene Inc. (NASDAQ: CLNN) stock closed at 2.9 per share at the end of the most recent trading day (a 4.69% change compared to the prior day closing price) with a volume of 2.29M shares and market capitalization of 183.44M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 74 people. Clene Inc. CEO is Robert Etherington.

The one-year performance of Clene Inc. stock is -75.18%, while year-to-date (YTD) performance is -29.27%. CLNN stock has a five-year performance of %. Its 52-week range is between 1.93 and 17.82, which gives CLNN stock a 52-week price range ratio of 6.10%

Clene Inc. currently has a PE ratio of 10.30, a price-to-book (PB) ratio of 74.33, a price-to-sale (PS) ratio of 277.63, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of 30.68%, a ROC of -43.13% and a ROE of -103.98%. The company’s profit margin is -%, its EBITDA margin is 3 391.30%, and its revenue ttm is $540.00 Thousand , which makes it $0.01 revenue per share.

Of the last four earnings reports from Clene Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.20 for the next earnings report. Clene Inc.’s next earnings report date is 09th Aug 2022.

The consensus rating of Wall Street analysts for Clene Inc. is Strong Buy (1), with a target price of $14.5, which is +400.00% compared to the current price. The earnings rating for Clene Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Clene Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Clene Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 41.67, ATR14 : 0.41, CCI20 : 28.68, Chaikin Money Flow : -0.13, MACD : 0.01, Money Flow Index : 62.29, ROC : -11.59, RSI : 52.80, STOCH (14,3) : 30.10, STOCH RSI : 1.00, UO : 51.45, Williams %R : -69.90), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Clene Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
6 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Clene Inc.

Clene Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for neurodegenerative diseases..

CEO: Robert Etherington

Telephone: +1 801 676-9695

Address: 6550 South Millrock Drive, Salt Lake City 84121, UT, US

Number of employees: 74

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

57%43%

Bearish Bullish

55%45%

TipRanks News for CLNN

Sat, 23 Apr 2022 09:09 GMT Analysts Offer Insights on Healthcare Companies: and Clene (CLNN)

- TipRanks. All rights reserved.

Sat, 23 Apr 2022 09:02 GMT Clene (CLNN) Gets a Buy Rating from Cantor Fitzgerald

- TipRanks. All rights reserved.

Thu, 17 Mar 2022 11:25 GMT Clene (CLNN) Receives a Buy from Maxim Group

- TipRanks. All rights reserved.

News

Stocktwits